Achondroplasia Clinical Trial
Official title:
Issues Surrounding Prenatal Genetic Testing for Achondroplasia
Since the gene responsible for achondroplasia was identified in 1994, it has become possible to test for achondroplasia prenatally. Moreover, prenatal genetic testing for achondroplasia is relatively simple and is highly likely to be informative for any couple seeking testing. Four diagnostic laboratories in the U.S. are currently performing prenatal genetic testing for achondroplasia. Before prenatal genetic testing for achondroplasia becomes more widely available, however, it is essential that we learn more about the lives of affected individuals and their families, the implications of offering testing for achondroplasia, and the education and the counseling needs of this community. Personal interviews and stories have been published and discussed at national meetings (Ablon 1984). We conducted a pilot telephone interview survey of 15 individuals with achondroplasia. What is needed now is a large scale quantitative study of the community of little people and their families. To meet this need, we have developed a survey tool to analyze family relationships, quality of life, tendencies toward optimism or pessimism, information-avoiding or information-seeking behaviors, social support, involvement in Little People of America Inc. (LPA), self-esteem, sociodemographics and views on achondroplasia, religiousness, reproductive and family plans, genetic testing, and abortion. The self-administered survey will be completed nationally by a sample of persons with achondroplasia and their family members.
Since the gene responsible for achondroplasia was identified in 1994, it has become possible to test for achondroplasia prenatally. Moreover, prenatal genetic testing for achondroplasia is relatively simple and is highly likely to be informative for any couple seeking testing. Four diagnostic laboratories in the U.S. are currently performing prenatal genetic testing for achondroplasia. Before prenatal genetic testing for achondroplasia becomes more widely available, however, it is essential that we learn more about the lives of affected individuals and their families, the implications of offering testing for achondroplasia, and the education and the counseling needs of this community. Personal interviews and stories have been published and discussed at national meetings (Ablon 1984). We conducted a pilot telephone interview survey of 15 individuals with achondroplasia. What is needed now is a large scale quantitative study of the community of little people and their families. To meet this need, we have developed a survey tool to analyze family relationships, quality of life, tendencies toward optimism or pessimism, information-avoiding or information-seeking behaviors, social support, involvement in Little People of America Inc. (LPA), self-esteem, sociodemographics and views on achondroplasia, religiousness, reproductive and family plans, genetic testing, and abortion. The self-administered survey will be completed nationally by a sample of persons with achondroplasia and their family members. ;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05353192 -
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
|
Phase 4 | |
Recruiting |
NCT05328050 -
Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
|
||
Completed |
NCT05659719 -
A Study to Learn About Recifercept in Patients With Achondroplasia
|
||
Active, not recruiting |
NCT04554940 -
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
|
Phase 2 | |
Completed |
NCT01435629 -
A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin
|
N/A | |
Enrolling by invitation |
NCT06164951 -
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
|
Phase 3 | |
Completed |
NCT01516229 -
Special Survey for Long Term Application
|
N/A | |
Completed |
NCT03872531 -
Lifetime Impact Study for Achondroplasia
|
||
Active, not recruiting |
NCT05598320 -
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
|
Phase 2/Phase 3 | |
Terminated |
NCT05813314 -
Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT04265651 -
Study of Infigratinib in Children With Achondroplasia
|
Phase 2 | |
Recruiting |
NCT05603936 -
Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Children From 0-4
|
||
Completed |
NCT03780153 -
The Norwegian Adult Achondroplasia Study
|
||
Active, not recruiting |
NCT04085523 -
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
|
Phase 2 | |
Enrolling by invitation |
NCT05929807 -
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06433557 -
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
|
Phase 2 | |
Completed |
NCT03875534 -
A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
|
||
Terminated |
NCT03794609 -
Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.
|
||
Completed |
NCT03583697 -
A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia
|
Phase 2 | |
Active, not recruiting |
NCT03989947 -
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
|
Phase 2 |